Then, we analysed PRMT5 expression in a panel of previously established/commercial (REN, IST‐Mes1, IST‐Mes2, MMB‐1, MPP 89 and NCI‐H2452) and patient‐derived primary (MMP1, MMP2, MMP4 and MMP6) MM cell lines and in normal mesothelial cells (LP‐9, HMC‐NEO, MeT‐5A and HMC1), by both real‐time quantitative reverse transcription‐PCR (qRT‐PCR) and Western blotting, and found that PRMT5 was expressed, although at different levels, in all the cells analysed (Figure 1F,G). Here, PRMT5 is linked to Miyoshi myopathy.